Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal M. Patel bought 53,300 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The stock was bought at an average price of $0.99 per share, with a total value of $52,767.00. Following the completion of the acquisition, the chief executive officer now owns 10,117,788 shares of the company's stock, valued at $10,016,610.12. This trade represents a 0.53 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Nautilus Biotechnology Price Performance
Shares of NASDAQ NAUT opened at $0.99 on Friday. The company has a market capitalization of $124.89 million, a price-to-earnings ratio of -1.77 and a beta of 1.25. The business has a 50-day moving average of $1.54 and a two-hundred day moving average of $2.11. Nautilus Biotechnology, Inc. has a 1 year low of $0.93 and a 1 year high of $3.09.
Hedge Funds Weigh In On Nautilus Biotechnology
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC purchased a new stake in shares of Nautilus Biotechnology during the 4th quarter worth approximately $44,000. Wexford Capital LP increased its position in shares of Nautilus Biotechnology by 42.4% during the fourth quarter. Wexford Capital LP now owns 325,239 shares of the company's stock worth $546,000 after purchasing an additional 96,889 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Nautilus Biotechnology in the 4th quarter valued at about $63,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Nautilus Biotechnology in the 4th quarter valued at about $34,000. Finally, Citadel Advisors LLC lifted its holdings in shares of Nautilus Biotechnology by 171.4% in the 4th quarter. Citadel Advisors LLC now owns 220,220 shares of the company's stock valued at $370,000 after purchasing an additional 139,081 shares during the last quarter. 50.71% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the company. The Goldman Sachs Group cut Nautilus Biotechnology from a "neutral" rating to a "sell" rating and decreased their price objective for the company from $2.25 to $1.75 in a research note on Thursday, December 5th. Guggenheim set a $2.50 price target on shares of Nautilus Biotechnology in a research note on Friday, February 28th.
Read Our Latest Stock Report on Nautilus Biotechnology
Nautilus Biotechnology Company Profile
(
Get Free Report)
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
